Robin Gasiorowski

9PUBLICATIONS
52CO-AUTHORS
Haematological tumoursMolecular targetsInstruments and techniquesPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 02, 2026
Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma.

|Aug 25, 2026
Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

|Jan 28, 2025
ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL.

Harry J Iland, John Reynolds, Alan V Boddy

|Sep 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial.

Catherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres

|Dec 22, 2022
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.

Catherine Thieblemont, Tycel Phillips, Herve Ghesquieres

|Apr 23, 2022
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.

Jonathan Wong, Emily Gruber, Belinda Maher

Pageof 2

Frequent Collaborators

2 joint publications

Judith Trotman

2 joint publications

Chan Y Cheah

2 joint publications

Michael Dickinson

2 joint publications

Tae Min Kim